Factors influencing response to ingenol mebutate therapy for actinic keratosis of face and scalp

doi:10.5306/wjco.v8.i5.405

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 8, Issue 5

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (7499)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-2) series, Tables (1-4) series.

Item

Count

PDF

365

WORD

251

HTML

2714

Figures (1-2)

184

Tables (1-4)

147

Sum=3661

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

793

Download

1268

Sum=2061

Publishing Process of This Article

Item

Count

Browse

607

Download

1170

Sum=1777

Oct 10, 2017 (publication date) through Apr 27, 2024

Times Cited of This Article

Times Cited (6)

Journal Information of This Article

Publication Name

World Journal of Clinical Oncology

ISSN

2218-4333

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Cohort Study

World J Clin Oncol. Oct 10, 2017; 8(5): 405-411
Published online Oct 10, 2017. doi: 10.5306/wjco.v8.i5.405

Table 4 Multivariate logistic regression backward analysis¹

	OR	95%CI for OR		P value
	OR	Lower	Upper	P value
Head site	5.19	1.51	17.86	0.009^a
LSR composite day 2	1.46	1.08	1.97	0.014^a
Crusting day 8	1.94	1.18	3.20	0.009^a
LSR composite max	1.50	1.02	2.21	0.038^a

¹Factors predicting response to ingenol mebutate 0.015% therapy. Logistic backward multivariate regression model. Reported OR mutually adjusted for all variables in the model. Variables in the model: Gender: Male (M), female (F); head site: Scalp, face; erythema at day 2, 3, 8, 15, 29, 57 and max; crusting at day 8 and max; swelling at day 2, 3, 8 and max; vesiculation/pustulation at day 2, 3 and max; ulceration at day 3; LSR composite at day 2, 3, 8, 15 and max.

^aP < 0.05. OR: Odds ratio; LSR: Local skin reaction.

Citation: Skroza N, Proietti I, Bernardini N, Balduzzi V, Mambrin A, Marchesiello A, Tolino E, Zuber S, La Torre G, Potenza C. Factors influencing response to ingenol mebutate therapy for actinic keratosis of face and scalp. World J Clin Oncol 2017; 8(5): 405-411
URL: https://www.wjgnet.com/2218-4333/full/v8/i5/405.htm
DOI: https://dx.doi.org/10.5306/wjco.v8.i5.405